ERAS

In the past six months, Erasca, Inc. (ERAS) stock has experienced significant volatility, with a 52-week range of $2.11 to $24.28 and a closing price of $14.58 as of October 2, 2026. Key events include a significant stock drop in April 2026 following disclosures of patent infringement allegations from Revolution Medicines concerning ERAS-0015 and adverse clinical data, including a patient death from pneumonitis, linked to the ERAS-0015 Phase 1 trial. These events led to multiple shareholder class action lawsuits alleging misleading statements by the company. In July 2026, Erasca completed an upsized public stock offering, raising approximately $550 million and extending its operational runway into the second half of 2028. The company also received FDA Fast Track Designation in August 2026 for ERAS-0015 in metastatic pancreatic adenocarcinoma. Despite legal and safety concerns, some analysts maintain a 'Buy' rating and have raised price targets, with a Street-high target of $30.00, viewing the approval of Revolution Medicines' RAS drug as validating the RAS mechanism.